Therapeutic Advances in Vaccines and Immunotherapy最新文献

{"title":"Predictors of Tdap vaccine acceptance in pregnancy before and after delivery.","authors":"David Toubiyan, Joshua Fogel, Allan J Jacobs","doi":"10.1177/25151355241287689","DOIUrl":"https://doi.org/10.1177/25151355241287689","url":null,"abstract":"<p><strong>Background: </strong>Tdap vaccine receipt in the immediate postpartum period has not been well studied.</p><p><strong>Objectives: </strong>We study factors associated with Tdap vaccine receipt during both pregnancy and the immediate postpartum period.</p><p><strong>Design: </strong>Retrospective study of 2844 pregnant patients that delivered.</p><p><strong>Methods: </strong>Factors from demographics, medical history, previous obstetric history, prenatal care, and previous vaccination history were included.</p><p><strong>Results: </strong>39.7% of patients received the Tdap vaccine, 39.5% received the Tdap vaccine prior to delivery, and 20.8% received the Tdap vaccine between delivery and discharge. Increased age (relative risk ratio (RRR): 0.98, 95% CI: 0.96, 0.99, <i>p</i> = 0.01) and lower number of prenatal care visits of fewer than 11 (RRR: 0.51, 95% CI: 0.41, 0.64, <i>p</i> < 0.001) were associated with decreased likelihood of vaccine receipt before delivery. Spanish language (before: RRR: 2.35, 95% CI: 1.69, 3.25, <i>p</i> < 0.001; after: RRR: 1.68, 95% CI: 1.13, 2.49, <i>p</i> = 0.01) and South Asian languages (before: RRR: 1.55, 95% CI: 1.03, 2.32, <i>p</i> = 0.04; after: RRR: 1.69, 95% CI: 1.06, 2.69, <i>p</i> = 0.03) had similar patterns for increased likelihood of Tdap vaccine receipt before and after delivery. Race/ethnicity of Hispanic (RRR:1.84, 95% CI: 1.31, 2.59, <i>p</i> = 0.001), Asian (RRR:1.65, 95% CI: 1.22, 2.22, <i>p</i> = 0.001), and receipt of influenza vaccine during current pregnancy (RRR: 1.58, 95% CI: 1.31, 1.91, <i>p</i> < 0.001) were associated with increased likelihood before delivery.</p><p><strong>Conclusion: </strong>Prenatal Tdap vaccination is the best way to prevent infection with <i>B. pertussis</i>. Postpartum Tdap vaccination provides some protection for those declining prenatal vaccination. We recommend that clinicians recognize that there are different patterns for Tdap vaccine receipt before and after delivery and tailor Tdap vaccine counseling based on these patterns.</p>","PeriodicalId":33285,"journal":{"name":"Therapeutic Advances in Vaccines and Immunotherapy","volume":"12 ","pages":"25151355241287689"},"PeriodicalIF":0.0,"publicationDate":"2024-10-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11472253/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142476429","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Vaccine skepticism and vaccine development stages; inoculation from \"cowpox\" lesion to the current mRNA vaccine of COVID-19: review.","authors":"Chernet Tafere, Desalegn Getnet Demsie, Bereket Bahiru Tefera, Adane Yehualaw, Kebede Feyisa, Malede Berihun Yismaw, Ashagrachew Tewabe Yayehrad","doi":"10.1177/25151355241288135","DOIUrl":"https://doi.org/10.1177/25151355241288135","url":null,"abstract":"<p><p>Global pandemics can be tackled by two means: lockdowns and vaccinations. As vaccination has a low impact on economic outcomes and better acceptance by people, it is the preferred method by most governments as a medium- to long-term solution. Vaccines have played a significant role in reducing the global burden of infectious diseases. They are designed to teach the immune system how to fight a particular infection before it causes a disease in subsequent exposures by creating a memory. Although vaccines effectiveness is well known, anti-vaccination movements pose significant challenges, even in high-income settings, leading to outbreaks of life-threatening infectious diseases. Hesitancy to take vaccines is not new and began with the first vaccination of smallpox. At that time, the problem was solved by a regulatory obligation to take vaccines, declared in England and Wales in 1853, which eventually led to its eradication in 1980. Different studies show that there is a decline in awareness of vaccines, hesitancy to take them, and concerns and trust issues regarding healthcare professionals. These problems have been rising over the past few decades for several reasons, notably, because of misinformation spread by social media. Therefore, the objective of this review is to provide a brief overview about vaccine hesitancy and attributable factors, illustrate the different types of vaccines, show the major challenges of vaccine development, and illustrate the pros and cons of each type.</p>","PeriodicalId":33285,"journal":{"name":"Therapeutic Advances in Vaccines and Immunotherapy","volume":"12 ","pages":"25151355241288135"},"PeriodicalIF":0.0,"publicationDate":"2024-10-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11471007/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142476430","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Multiple myeloma and the potential of new checkpoint inhibitors for immunotherapy.","authors":"Ali N Kamali, Haleh Hamedifar, Michael Eisenhut, Jose M Bautista","doi":"10.1177/25151355241288453","DOIUrl":"https://doi.org/10.1177/25151355241288453","url":null,"abstract":"<p><p>Multiple myeloma (MM), a cancer of the bone marrow, is categorized as the second most common hematological malignancy of adults in the Western world. Despite dramatic improvements in immunotherapies in the field of cancers, MM immunotherapy has not been promising until now. Recent clinical studies of immune checkpoint inhibitor therapy, either alone or in combination with anticancer drugs, showed excessive side effects or low efficacy, particularly in advanced MM patients. In this context, lymphocyte levels of exhaustion markers play a pivotal role in the MM tumor microenvironment (TME). Hence in the present review, the mechanisms relevant to MM of five inhibitory molecules including T-cell immunoreceptor with Ig and ITIM domains (TIGIT), T-cell immunoglobulin, and mucin domain 3 (Tim-3), lymphocyte activation gene-3 (LAG-3), V-domain Ig Suppressor of T-cell activation and killer immunoglobulin-like receptors along with bispecific T-cell antibodies (BsAbs) will be discussed. Further, we summarized the underlying biology of these checkpoints in cancer and their rapidly emerging role in pathways in MM along with presenting recent clinical trials in context.</p>","PeriodicalId":33285,"journal":{"name":"Therapeutic Advances in Vaccines and Immunotherapy","volume":"12 ","pages":"25151355241288453"},"PeriodicalIF":0.0,"publicationDate":"2024-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11467827/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142476428","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploring COVID-19 vaccine adverse events among pregnant women: a cross-sectional study, 2022.","authors":"Ahmed A Amer, Samar A Amer, Amerah Badokhon, Sherif M Hammad, Mohamed A Wasfy, Misha Khan, Tahani Ateyah Al-Harbi, Sadah Qamous Alobaid, Georgette Eskander, Amro Abdel-Azeem, Abdulmajeed Alshowair, Mohamed Sh Ramadan","doi":"10.1177/25151355241285594","DOIUrl":"https://doi.org/10.1177/25151355241285594","url":null,"abstract":"<p><strong>Background: </strong>Clear and trustworthy information is crucial to improving public acceptance of COVID-19 vaccinations, especially among pregnant women. Given the increased risk of severe viral pneumonia in pregnant women, it is critical to foster confidence in the vaccine's safety and understand any potential adverse events (AEs). So, we did this study in Jeddah, Saudi Arabia (SA), from March to May 2022 to compare women who did not get any doses of the COVID-19 vaccine during pregnancy (Group A) to women who did get at least one dose during pregnancy (Group B) regarding (1) the frequency, types, AEs, and management of its AEs of the COVID-19 vaccination; and (2) exploring pregnancy, delivery, and fetus-related complications (e.g., miscarriage, birth defects, and preterm labor).</p><p><strong>Methods: </strong>A cross-sectional study targeted 438 women who gave birth or were pregnant within the previous 8 weeks. Data was collected through face-to-face interviews with skilled nurses in 13 randomly selected primary healthcare facilities, using a validated, well-structured questionnaire that included the Centers for Disease Control (CDC) COVID-19 vaccination-related AEs. We analyzed the collected data using SPSS version 27.</p><p><strong>Results: </strong>Most participants were aged 25 to less than 35 (58.8%), and 287 (61.3%) were university graduates. There was no statistically significant difference among the studied groups regarding demographics. However, women in Group B had a significantly higher rate of abortions, oligohydramnios (24.4%), abnormal placentas (size and location), 103 (42.7%) abnormal fetal growth, 122 (53.7%) problems breastfeeding, blood pressure problems, and more cases of malaise, headaches, chest pain, breathing problems, and sleep problems than women in Group A. After the second and third doses, the confirmed post-vaccination COVID-19 rates in Group B were lower than those in Group A.</p><p><strong>Conclusion: </strong>The COVID-19 vaccine significantly reduces post-vaccination COVID-19. Although COVID-19 vaccine-related AES are prevalent, analgesics and antipyretics effectively treat most of them.</p>","PeriodicalId":33285,"journal":{"name":"Therapeutic Advances in Vaccines and Immunotherapy","volume":"12 ","pages":"25151355241285594"},"PeriodicalIF":0.0,"publicationDate":"2024-10-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11457191/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142393855","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Relative effectiveness of COVID-19 vaccine booster doses in people aged 65 and older-a retrospective cohort study in Türkiye.","authors":"Mehmet Akif Sezerol, Alican Sarisaltik","doi":"10.1177/25151355241285375","DOIUrl":"10.1177/25151355241285375","url":null,"abstract":"<p><strong>Background: </strong>Immunization in the elderly population is critical due to the high frequency of health outcomes related to COVID-19.</p><p><strong>Objectives: </strong>This study aimed to compare the effectiveness levels of COVID-19 vaccine schedules in preventing SARS-CoV-2 infection in the older adult group who received at least one booster dose.</p><p><strong>Design: </strong>Retrospective cohort study.</p><p><strong>Methods: </strong>This study evaluated 8969 adults aged 65 and over in the Sultanbeyli district of İstanbul. COVID-19 vaccination and SARS-CoV-2 polymerase chain reaction testing data between January 14, 2021 and December 2, 2022 were obtained from the National Public Health Management System.</p><p><strong>Results: </strong>The median age of participants was 71 years. The vaccines were mostly administered as CoronaVac for the first and second doses (81.4% and 82.2%, respectively) and BNT162b2 for the third and fourth doses (61.8% and 73.1%, respectively). Turkovac was administered only in booster doses (third dose 0.6%, fourth dose 4.8%). The adjusted relative vaccine effectiveness (rVE) was found to be 61.8% (95% confidence interval (CI) 51.5-69.9) in two doses of inactivated vaccine and one dose of mRNA vaccine schedule compared to the homolog booster of CoronaVac primary vaccine schedule. In two booster doses receipts, the adjusted rVE was found to be 45.4% (95% CI 13.8-65.4) in three doses of inactivated and one dose mRNA vaccine schedule and 43.0% (95% CI 20.5-59.2) in two doses of inactivated and two doses of mRNA vaccines schedule compared to the two homolog boosters with CoronaVac primary vaccine schedule.</p><p><strong>Conclusion: </strong>In this study, the effectiveness of the mRNA vaccine as a booster dose was higher than that of the homologous boosters in participants receiving the CoronaVac primary series for those aged 65 and over.</p>","PeriodicalId":33285,"journal":{"name":"Therapeutic Advances in Vaccines and Immunotherapy","volume":"12 ","pages":"25151355241285375"},"PeriodicalIF":0.0,"publicationDate":"2024-09-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11452850/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142381796","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"COVID-19 vaccine coverage effectiveness among elderly with geographical information system mapping: what about Indonesia?","authors":"Widya Ratna Wulan, Evina Widianawati, Anis Tri Wahyuni","doi":"10.1177/25151355241285379","DOIUrl":"10.1177/25151355241285379","url":null,"abstract":"<p><strong>Background: </strong>The elderly are the next priority after health workers and public service workers get the COVID-19 vaccine to control morbidity and even mortality in the elderly who have a risk factor that is up to 60 times more severe than children.</p><p><strong>Objectives: </strong>This study aimed to spatially analyze the effectiveness of COVID-19 vaccine coverage among the elderly in Indonesia with geographic information system (GIS) mapping and to analyze the relationship between COVID-19 vaccine coverage in the elderly with the COVID-19 cure rate.</p><p><strong>Design: </strong>This quantitative study used secondary data on COVID-19 vaccination coverage in the elderly group of Central Java Province, Indonesia in 2021.</p><p><strong>Methods: </strong>Data were analyzed using a simple linear correlation test to test the relationship between variables with a 1,774,396 elderly sample size, then distributed using mapping of COVID-19 vaccination coverage using a GIS.</p><p><strong>Results: </strong>The relationship between COVID-19 vaccine dose-2 elderly coverage cure rate showed a strong relationship (<i>r</i> = 0.677) and a positive pattern. The coefficient value with a determination of 0.459 means that the regression line equation obtained can explain 45.90% of the variation in the COVID-19 cure rate. There was a significant relationship between COVID-19 vaccine elderly coverage and the COVID-19 cure rate (<i>p</i>-value = 0.005).</p><p><strong>Conclusion: </strong>Clinicians and public health workers should continue to encourage elderly vaccination at all recommended doses for eligible individuals.</p>","PeriodicalId":33285,"journal":{"name":"Therapeutic Advances in Vaccines and Immunotherapy","volume":"12 ","pages":"25151355241285379"},"PeriodicalIF":0.0,"publicationDate":"2024-09-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11456189/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142381795","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Knowledge, attitude, and acceptance of COVID-19 vaccine in pregnant women.","authors":"Arissara Kuptarak, Vorapong Phupong","doi":"10.1177/25151355241278832","DOIUrl":"https://doi.org/10.1177/25151355241278832","url":null,"abstract":"<p><strong>Background: </strong>Due to the COVID-19 situation, vaccination is a key factor in reducing the severity and transmission of the disease, especially in the vulnerable population, which includes pregnant women. Currently, various policies are in place to promote the vaccination of pregnant women against COVID-19; however, some pregnant women decline vaccination.</p><p><strong>Objectives: </strong>To study pregnant women's knowledge, attitude, and acceptance regarding the COVID-19 vaccine.</p><p><strong>Design: </strong>A cross-sectional study was conducted among pregnant women who received antenatal care at King Chulalongkorn Memorial Hospital, Chulalongkorn University, Bangkok, Thailand.</p><p><strong>Methods: </strong>Pregnant women who received antenatal care at King Chulalongkorn Memorial Hospital, Chulalongkorn University from November 2021 to April 2022 were included. The participants answered an online questionnaire through their electronic devices. Univariate and multivariate logistic regression analyses were performed to analyze the data.</p><p><strong>Results: </strong>A total of 500 pregnant women participated in this study. Among them, 67.4% and 81.4% had great knowledge and a positive attitude toward the COVID-19 vaccine, respectively, with scores of 80% or higher in each section. Of the 500 participants, 468 (93.6%) accepted to receive the COVID-19 vaccine. After adjusting for certain variables through multivariate analysis, the factor associated with the decision to receive the COVID-19 vaccine was having great knowledge about the vaccine (adjusted odds ratio (OR) 13.25, 95% confidence interval (CI) 2.45-71.61). However, the most significant factor associated with the decision to reject the COVID-19 vaccine was the recent COVID-19 infection (adjusted OR 0.11, 95% CI 0.02-0.62).</p><p><strong>Conclusion: </strong>The COVID-19 pandemic presents severe and life-threatening conditions for both pregnant women and their fetuses. The majority of the pregnant women in this study had great knowledge and acceptance of the vaccine and a positive attitude toward it. The pregnant women who had prior knowledge of the vaccine tended to accept to receive it during pregnancy, whereas those who recently contracted COVID-19 were hesitant to receive the vaccine.</p>","PeriodicalId":33285,"journal":{"name":"Therapeutic Advances in Vaccines and Immunotherapy","volume":"12 ","pages":"25151355241278832"},"PeriodicalIF":0.0,"publicationDate":"2024-09-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11428176/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142355496","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparative 60-day effectiveness of bivalent versus monovalent mRNA vaccines in Shelby County: a population-level analysis.","authors":"Allison P Plaxco, Jennifer Kmet, Matthew P Smeltzer, Yu Jiang, Michelle Taylor, Vikki G Nolan","doi":"10.1177/25151355241278852","DOIUrl":"10.1177/25151355241278852","url":null,"abstract":"<p><strong>Background: </strong>Two monovalent mRNA vaccines, available in December 2020, were demonstrated to have high efficacy against both the original SARS-CoV-2 strain and variants circulating through the summer and into the fall of 2021. In the context of the Omicron/BA.1 variant, which was predominant from late fall 2021 into winter of 2022 in the United States, and subsequent Omicron subvariants that have been predominant thereafter, vaccine effectiveness of the monovalent mRNA vaccine option is attenuated.</p><p><strong>Objectives: </strong>We aim to investigate the relative effectiveness of the bivalent booster compared to the monovalent booster against SARS-CoV-2 infection in the 60 days following administration in Shelby County, TN.</p><p><strong>Design: </strong>This observational population-based cohort study utilizes COVID-19 surveillance data to identify adults who were vaccinated with a monovalent booster dose between August 1, 2022 and August 30, 2022 or a bivalent booster dose between September 1, 2022 and September 30, 2022. Both groups were followed for COVID-19 status for 60 days from their administration date.</p><p><strong>Methods: </strong>We calculated incidence rates with 95% confidence intervals and propensity-adjusted hazard ratios with 95% confidence intervals of COVID-19 diagnosis in the 60 days following administration of the booster dose between the bivalent group and the monovalent group. Stratified analysis was conducted by age group (18-34, 35-64, and 65+ years old).</p><p><strong>Results: </strong>The incidence of reported SARS-CoV-2 infection was substantially higher for those who received the monovalent booster, across age groups. Overall, we observed a 51% lower hazard of infection during the study period among those who received the bivalent booster, compared to the monovalent booster.</p><p><strong>Conclusion: </strong>These results support and extend prior findings that the bivalent booster dose may be more effective in preventing infection against the Omicron sub-variants of SARS-CoV-2.</p>","PeriodicalId":33285,"journal":{"name":"Therapeutic Advances in Vaccines and Immunotherapy","volume":"12 ","pages":"25151355241278852"},"PeriodicalIF":0.0,"publicationDate":"2024-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11418355/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142308681","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Vaccination practices and knowledge among adults with hemoglobinopathies in Greece: a nationwide survey.","authors":"Sophia Delicou, Konstantinos Manganas, Aikaterini Xydaki, Loukia Evliati, Ioanna Myrilla, Leonidas Rubatis, Stavroula Kostaridou","doi":"10.1177/25151355241278869","DOIUrl":"10.1177/25151355241278869","url":null,"abstract":"<p><strong>Background: </strong>Hemoglobinopathies, such as sickle cell disease and thalassemia, are genetic disorders that affect hemoglobin structure or production, leading to various health complications, including an increased risk of infections. Vaccinations play a crucial role in managing these conditions by providing essential protection against preventable diseases. Ensuring timely and appropriate immunizations is vital for reducing infection-related morbidity and improving the overall health and quality of life for affected individuals.</p><p><strong>Objectives: </strong>Our objective was to assess vaccination coverage, as well as knowledge, attitudes, and practices toward vaccination in Greek patients with hemoglobinopathies.</p><p><strong>Design and methods: </strong>A nationwide survey of hemoglobinopathy patients in Greece using a 37-item questionnaire was conducted anonymously via Google Forms. It covered demographics, previous vaccinations, vaccine-preventable infections, beliefs about vaccines, and antibiotic prophylaxis post-splenectomy. The survey was distributed through Thalassemia and Sickle Cell Units and organizations.</p><p><strong>Results: </strong>Participants were predominantly university-educated married women aged 30-50 years with transfusion-depended thalassemia (<i>n</i> = 149, 60.5%) or sickle cell anemia (<i>n</i> = 52, 21.1%). Reported childhood vaccination rates aligned with Greece's national immunization program. However, adult coverage was suboptimal across all age groups for measles (10%), varicella (27%), zoster (2% for over 50 years old individuals), hepatitis A (13.9% of those with chronic liver disease) and hepatitis B (41%), pneumococcal (81.3%), meningococcal (37%), tetanus (20.3%), and influenza (67.1%) vaccines compared to guidelines. Participants relied predominantly on healthcare providers for vaccine information but perceived limited engagement. Those over age 50 demonstrated lower adult vaccination rates and higher misconceptions compared to younger cohorts.</p><p><strong>Conclusion: </strong>Addressing educational and access gaps could help protect this vulnerable population. Our findings highlight the need for coordinated efforts to optimize adult immunization for those with hemoglobinopathies.</p>","PeriodicalId":33285,"journal":{"name":"Therapeutic Advances in Vaccines and Immunotherapy","volume":"12 ","pages":"25151355241278869"},"PeriodicalIF":0.0,"publicationDate":"2024-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11418312/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142308682","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Media literacy: exploring the key to social media influences for wise parental decision-making on vaccines.","authors":"Dalmacito A Cordero","doi":"10.1177/25151355241277780","DOIUrl":"https://doi.org/10.1177/25151355241277780","url":null,"abstract":"","PeriodicalId":33285,"journal":{"name":"Therapeutic Advances in Vaccines and Immunotherapy","volume":"12 ","pages":"25151355241277780"},"PeriodicalIF":0.0,"publicationDate":"2024-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11402060/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142297008","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}